Pazopanib - GlaxoSmithKline/Novartis

Drug Profile

Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 08 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Duke University Medical Center; GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; Northwestern University; Novartis; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Heidelberg; University of Minnesota; University of Oxford; University of Washington
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastrointestinal stromal tumours; Glioma; Haemangiosarcoma; Liposarcoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Malignant melanoma
  • No development reported Colorectal cancer; Liver cancer
  • Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

  • 08 Oct 2018 Pazopanib is still in phase II trials for Prostate cancer (Neoadjuvant therapy, First-line therapy) in USA (PO) (NCT01832259)
  • 12 Sep 2018 University of Washington plans a phase I/II trial for Soft tissue sarcoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA in October 2018 (NCT03660930)
  • 09 Aug 2018 University of Utah and Novartis completes a phase II trials for Prostate cancer (Neoadjuvant therapy, First-line therapy) in USA (PO) (NCT01832259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top